Tag: Human Papillomavirus (HPV)

Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100

Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years

However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults

Risk increased for both persistent and placental infection and for both spontaneous and all preterm births

Despite 79.9 percent increase in parent-reported safety concerns, there was a drop in HPV vaccine-related reported adverse reactions

Beta-HPV detected in skin swabs may predict cuSCC risk, but no link seen for serologic evidence of past beta-HPV infection

Rates low for 18- to 21-year-olds reporting vaccination at any age or initiating in young adulthood

For most of the study period, higher rates of HPV vaccination initiation and up-to-date rates were seen for non-Hispanic Blacks, Hispanics

Persistent, oral, high-risk HPV infection for children linked to oral HPV carriage of mother at birth, seroconversion of mother to high-risk HPV

However, more unvaccinated teens receiving provider recommendation for HPV vaccination; findings consistent for boys and girls